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ABSTRACT 
The early progression of diabetic nephropathy is notoriously difficult to detect and quantify prior to 
the occurrence of substantial histological damage. Recently, hyperpolarized [1-13C] pyruvate has 
demonstrated increased lactate production in the kidney early after the onset of diabetes, implying 
increased lactate dehydrogenase activity as a consequence of increased nicotinamide adenine 
dinucleotide substrate availability due to upregulation of the polyol pathway, i.e., pseudohypoxia. In 
this study, we investigated the role of oxidative stress in mediating these metabolic alterations using 
state-of-the-art hyperpolarized magnetic resonance (MR) imaging. 
Ten-week-old female Wistar rats were randomly divided into three groups: healthy controls, 
untreated diabetic (streptozotocin treatment to induce insulinopenic diabetes), and diabetic, 
receiving chronic antioxidant treatment with TEMPOL (4-hydroxy-2,2,6,6-tetramethylpiperidin-1-
oxyl) via the drinking water. Examinations were performed 2, 3, and 4 weeks after the induction of 
diabetes by using a 3T Clinical MR system equipped with a dual tuned 13C/1H-volume rat coil. The 
rats received intravenous hyperpolarized [1-13C] pyruvate and were imaged using a slice-selective 
13C-IDEAL spiral sequence. 
Untreated diabetic rats showed increased renal lactate production compared to that shown by the 
controls. However, chronic TEMPOL treatment significantly attenuated diabetes-induced lactate 
production. No significant effects of diabetes or TEMPOL were observed on 13C-alanine levels, 
indicating an intact glucose-alanine cycle, or 13C-bicarbonate, indicating normal flux through the 
Krebs cycle. 
In conclusion, this study demonstrates that diabetes-induced pseudohypoxia, as indicated by an 
increased lactate-to-pyruvate ratio, is significantly attenuated by antioxidant treatment. This 
demonstrates a pivotal role of oxidative stress for renal metabolic alterations occurring in early 
diabetes.  
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INTRODUCTION 
Patients diagnosed with developing diabetic nephropathy are left with current treatments that at best 
slow disease progression (19). Thus, effective prevention and treatment of diabetic nephropathy 
requires a better understanding of the mechanisms involved in progressive kidney damage. Today, 
microalbuminuria is the preferred marker of diabetic nephropathy, but by the time 
microalbuminuria can be detected, abnormal renal structural changes have already occurred. 
Hyperpolarized 13C-labeled pyruvate was recently introduced as a possible alternative endogenous 
marker for the identification of renal metabolic alterations in diabetic rats. This technique allows for 
real-time repeated measurements of intrarenal metabolism during the development of kidney 
disease (5-7). Prolonged hyperglycemia causes altered oxygen metabolism via an increased flux 
through the polyol pathway, leading to imbalanced NADH/NAD+ distribution, which in turn 
increases lactate formation even though sufficient oxygen is present for oxidative phosphorylation 
to occur. Such a metabolic alteration is commonly referred to as pseudohypoxia (25). However, 
despite the name, pseudohypoxia will eventually result in the development of “true” renal hypoxia 
as the disease progresses (3, 15). Thus, the balance between pseudohypoxic and hypoxic conditions 
has been proposed to be an indication of disease progression (5-7). 
Oxidative stress has been reported to be a crucial component of diabetic nephropathy, and 
antioxidant treatment in animal models of diabetic nephropathy has generally resulted in reduction 
or even complete prevention of disease progression (24). The relationship between increased 
oxidative stress and metabolic alterations in the diabetic kidney has not been established, although a 
close relationship between metabolic alteration and development of diabetic nephropathy has been 
reported (15). Therefore, we tested the hypothesis that chronic antioxidant treatment prevents 
pseudohypoxia in a rat model of insulinopenic diabetes using hyperpolarized metabolic imaging.  
5  
MATERIALS AND METHODS 
Twenty-four ten-week-old female Wistar rats (Taconic, Ry, Denmark) were included in this study. 
The rats were randomly grouped into an untreated diabetic group (n=14), a 4-hydroxy-2,2,6,6-
tetramethylpiperidin-1-oxyl (TEMPOL)-treated diabetic group (n=8), and a healthy control group 
(n=6). Diabetes was induced by an intravenous injection of freshly prepared streptozotocin (STZ; 
55 mg/kg body weight; Sigma-Aldrich, St. Louis, MO, USA) dissolved in 10 mmol/L cold citrate 
buffer (pH 4.5). Blood glucose was measured in tail-capillary blood with a Contour XT blood 
glucose meter (Bayer Diabetes Care, Copenhagen, Denmark). Rats were considered diabetic if 
blood glucose levels exceeded 15 mmol/L at 48h after STZ injection. In order to identify the 
development of diabetic complications, a longitudinal within-subject study design was used for the 
analysis of the development of diabetic nephropathy. This part of the study was performed on 
healthy (N=6) and N=10 (data from two rats were excluded from the diabetic group due to 
erroneous MRI acquisitions and only a single time point of data acquisition, resulting in (N=8)) 
animals with up to three examinations per animal. The examinations were performed at two, three, 
and four weeks after diabetes induction (Fig. 1A). In order to identify the response to TEMPOL 
treatment a parallel group was investigated at only one time point consisting of untreated diabetic 
(N=4, test of difference with within-subject diabetic animals) and TEMPOL treated diabetic 
animals (N=8) at the terminal point (Fig. 1B). No difference was found between the longitudinal 
and the single time point diabetic groups at the terminal point. The study complied with the 
Guidelines for Use and Care of Laboratory Animals and was approved by the Danish Inspectorate 
of Animal Experiments. 
Tail vein catheterization was performed for hyperpolarized [1-13C] pyruvate administration, and 
then the animals were placed in a clinical magnetic resonance (MR) scanner for metabolic imaging. 
Temperature, oxygen saturation, and respiration were monitored throughout the MR imaging 
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session (SA Instruments, Stony Brook, NY, USA). After the final MR imaging (MRI) session, a 
blood sample was collected from the aortic bifurcation using ethylenediaminetetraacetic acid 
(EDTA) coated tubes. MRI sessions were performed on a 3T HDx clinical scanner (GE Healthcare, 
Waukesha, WI, USA) equipped with a dual tuned 1H/13C-volume transmit/receive rat radio 
frequency coil (GE Healthcare, Waukesha, WI, USA). The kidneys were localized by a standard 
localization sequence. Axial, coronal, and oblique 1H-T2 weighted fast spin echo experiments were 
used for metabolic overlay and anatomical information. The sequence parameters were: 
matrix=384x384 (interpolated to 512x512), field of view (FOV)=80x80 mm2, flip angle=90°, 
repetition time (TR)=3000 ms, number of transients=16, number of echoes=28, echo time 
(TE)=104, 3-7 slices of 5 mm thickness, covering both kidneys in axial, coronal, and oblique 
orientations. A slice-selective 13C-IDEAL spiral sequence was used for hyperpolarized [1-13C] 
pyruvate imaging, acquiring images every 5 s and initiated 20 s after the start of injection. Sequence 
parameters were as follows: a flip angle of 10º, 11 IDEAL echoes and one initial spectrum per 
IDEAL encoding, TR/TE/ΔTE=100 ms/0.9 ms/0.9 ms, FOV=80x80 mm2, 5x5 mm real resolution 
and an axial slice thickness of 15 mm covering both kidneys. 
 
Hyperpolarization 
A solution of 127 mg of [1-13C] pyruvic acid (Cambridge Isotope Laboratories, Tewksbury, MA) 
mixed with 15 mM AH111501 (GE Healthcare, Brøndby, DK) was polarized in a 5T SPINlab (GE 
Healthcare, Brøndby, DK), to a reproducible polarization of more than 40% with a final 
concentration of 125 mM. 
 
MRI Analysis 
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Data analysis of the hyperpolarized MR signal was processed using a vendor delivered Matlab 
(MathWorks, Natick, MA, USA) package, and the raw DICOM images were transferred to OsiriX 
(Pixmeo, Geneva, Switzerland) for anatomical overlay and region of interest (ROI) analysis. The 
metabolite signal was normalized relative to the pyruvate signal in each individual kidney. 
 
Quantitative real-time PCR 
After euthanasia, kidney cortices were rapidly dissected and snap-frozen in liquid nitrogen. Cortical 
tissue was homogenized and total RNA was isolated using a Nucleospin RNA II kit (Stratagene; 
AH Diagnostics, Aarhus, DK) following the manufacturer’s instructions. RNA purity and 
concentration was measured spectrophotometrically (Eppendorf Biophotometer, Hørsholm, 
Denmark). cDNA synthesis was performed on 0.5 µg RNA with a revert first strand cDNA 
synthesis kit (Thermo Scientific, Hvidovre, DK) according to the manufacturer’s instructions. 
Preparation of samples for qPCR was performed using Maxima SYBR Green qPCR master mix 
(Thermo Scientific, Hvidovre, DK), following the manufacturer’s instructions. The qPCR protocol 
consisted of 40 cycles of: denaturation for 30 seconds at 95°C followed by annealing and synthesis 
for 1 min at 60°C, and was performed in a 96-well qPCR plate using an AriaMx PCR system 
(Agilent Technology, Glostrup, Denmark). Primer information for each individual gene is presented 
in Table 1. 
 
Biochemical assays and ELISA for KIM-1 and NGAL 
Fumarate, lactate and succinate assays (Sigma-Aldrich) and ELISA for Kidney injury marker 1 
(KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) ELISA (Abcam, Cambridge, UK) 
were performed according to the manufacturer’s instructions  In brief, kidney cortex tissue was 
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snap-frozen in liquid nitrogen. Thereafter, tissue was homogenized in assay buffer specific for each 
assay; the homogenate centrifuged, and assays and ELISA performed on the resultant supernatant. 
Blood was collected from the abdominal aorta, transferred to heparin tubes and centrifuged to 
isolate the plasma fraction. All samples were stored at -80◦C. Analysis was performed in 96-well 
Costar plates in a PHERAstar FS micro plate reader (BMG Labtech, Birkerød, Denmark). The full 
absorbance spectrum was determined for each wavelength in order to optimize each assay. 
 
Statistics 
Normality was assessed with quantile plots. Two-sided p<0.05 was considered statistically 
significant. A multivariate repeated measure analysis of variance (ANOVA) based on the mixed 
model approach to allow missing values was used to compare the metabolic response as a function 
of time and performed using STATA (StataCorp LP, TX, USA). No additional post hoc corrections 
were performed. If the mean response (within-subjects, between-subject, and interaction) was 
significantly different, a pairwise comparison of the individual time points was performed. 
The group differences at the terminal point (Fig. 1B) to investigate the treatment response to 
TEMPOL and the biochemical analysis were performed using a one-way-ANOVA with Fisher post 
hoc correction using GraphPad, Prism (GraphPad Inc. La Jolla, CA, USA). 
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RESULTS 
Administration of STZ resulted in hyperglycemia within 48h, and blood glucose levels remained 
significantly elevated throughout the study period (p<0.0001; Fig. 2). Diabetic animals developed 
pronounced renal hypertrophy (p<0.0001), while total body weight did not significantly differ 
between the groups (p=0.3; Fig. 2). Chronic TEMPOL treatment to diabetic animals did not 
significantly affect any of these parameters compared to the untreated diabetic group (Fig. 2). 
The lactate-to-pyruvate ratio was significantly elevated in the diabetic kidney at three weeks (+38% 
versus healthy controls; p=0.01) and further increased (+77% versus healthy control; p=0.001) at 
four weeks after the induction of diabetes (Fig. 3, Table 2). No significant time-dependent changes 
between healthy controls and diabetic rats were observed for either alanine-to-pyruvate or 
bicarbonate-to-pyruvate ratios, although a significant overall time dependency was found in the 
bicarbonate-to-pyruvate ratio (Fig. 3, Table 2). Chronic TEMPOL treatment significantly reduced 
lactate production (p=0.03) compared to untreated diabetic rats, but had no effect on alanine 
(p=0.47) or bicarbonate levels (p=0.11; Fig. 4). 
The mRNA expression of lactate dehydrogenase was significantly elevated in the diabetic group 
compared to healthy controls (p=0.01). Chronic TEMPOL treatment significantly attenuated this 
increase, as treated animals presented a similar expression level as controls (p=0.5; Fig. 5). mRNA 
expression of pyruvate dehydrogenase (p=0.09) and alanine transferase (p=0.2) was similar in all 
groups (Fig. 5). No significant differences were observed in mRNA expression of oxygen-sensitive 
genes, kidney injury markers, or inflammation markers (Fig. 6). Chronic TEMPOL treatment 
significantly decreased cortical tissue lactate concentration in both controls (p=0.046) and diabetics 
(p=0.0025), while a significantly increased lactate concentration was seen in plasma compared to 
untreated controls (p=0.013). The concentration of the TCA intermediate fumarate was similarly 
significantly reduced by chronic TEMPOL treatment in cortical tissue compare to controls 
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(p=0.002) and diabetic (p=0.031) animals. Succinate concentrations, was significantly increased in 
both diabetic animals with (p=0.001) and without (p<0.001) chronic TEMPOL treatment. No 
significant differences were observed in either succinate or fumarate concentrations in plasma (Fig. 
7). No significant different concentrations of NGAL (p=0.072) or KIM-1 concentration (p=0.095) 
between controls and diabetic animals with and without chronic TEMPOL treatment (Fig. 8).   
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DISCUSSION 
The main finding of this study was that antioxidant treatment with TEMPOL attenuated diabetes-
induced lactate formation, and thus improved the lactate-to-pyruvate ratio in diabetic animals. This 
finding implies improved metabolic status secondary to reduced pseudohypoxia and supports the 
use of hyperpolarized [1-13C] pyruvate as a biomarker for renal metabolic status under different 
treatment regimens. TEMPOL is a potent antioxidant known to prevent oxidative stress and to 
improve insulin sensitivity (2). Interestingly, we have recently shown that suboptimal insulin 
treatment does not improve the lactate-to-pyruvate ratio (5), indicating that the main mechanism for 
the phenomenon seen in TEMPOL-treated animals is likely due to direct antioxidant effects. 
The diabetic kidney suffers from altered metabolism, manifesting as increased total oxygen 
consumption secondary to increased mitochondrial leak respiration and decreased tubular 
electrolyte transport efficiency (4). Furthermore, increased metabolic flux via the polyol pathway 
causing altered cellular NADH/NAD+ ratio results in increased lactate production and increased 
lactate-to-pyruvate ratio despite sufficient oxygen availability for oxidative phosphorylation (3). 
This condition is therefore commonly referred to as “pseudohypoxia.” (25). It has been 
demonstrated that the inhibition of aldose reductase, the initial step in the polyol pathway, 
effectively prevents increased lactate formation and the subsequent reduction of the interstitial pH 
in the diabetic kidney (15). Indeed, most data supporting an altered NADH/NAD+ ratio originate 
from in vitro experiments (13) due to the methodological difficulties in obtaining reliable and 
reproducible results from in vivo approaches. The present study demonstrates, using a non-invasive 
imaging method that only requires an intravenous injection of the tracer, a novel link between 
oxidative stress and pseudohypoxia in the diabetic kidney. This provides an additional mechanistic 
explanation for the beneficial effects of antioxidant treatment on diabetic kidney function (14, 17). 
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The lactate-to-pyruvate ratio depends on the degree of diabetes-induced kidney damage, whereas 
alanine transferase and pyruvate dehydrogenase activity seems to be largely unaffected. This is in 
agreement with our previous findings, which reported increased intrarenal lactate-to-pyruvate ratios 
in insulinopenic rats (5-7). Furthermore, a time-dependent accumulation of lactate in the diabetic 
kidney has been previously reported as well (8). The decreased cortical lactate concentration in 
response to TEMPOL treatment is in good agreement with the findings using hyperpolarized [1-
13C]pyruvate. It has previously been reported that increased succinate concentrations stimulate renin 
release (21). Succinate is converted by succinate dehydrogenase into fumarate in the TCA cycle and 
we therefore investigated the pool size of fumarate. An inverse relationship between fumarate and 
succinate was observed. This is contrary to previous studies reporting significantly elevated 
fumarate concentrations in another animal model of experimental diabetes (26). It can be speculated 
that varying severity of diabetes and different animal models may influence these findings. 
However, it was previously demonstrated that treatment with an NOX1/NOX4 inhibitor decreased 
fumarate levels, implying a pivotal involvement of oxidative stress. This is in agreement with the 
results from the present study demonstrating that the antioxidant TEMPOL significantly alters this 
metabolic pathway. However, it should be noted that PDH flux was unaltered and that leak 
respiration provides a substantial contribution to total kidney oxygen consumption in diabetes (17). 
Necrosis and subsequent cellular leak could be a potential mechanism for increased extracellular 
concentrations of TCA metabolites (21,26). Although the lactate-to-pyruvate ratio was significantly 
increased in the diabetic kidney, the mRNA expression of oxygen-sensitive and renal dysregulation 
genes were not altered, suggesting an earlier identification of the renal abnormalities observed using 
hyperpolarized MR. 
Biomarkers for kidney injury, such as NGAL and KIM1, have been demonstrated to correlate with 
loss of kidney function in patients with type-2 diabetes (12). Elevated levels of these kidney injury 
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markers have also been reported in experimental models of insulinopenic diabetes (1,22,23). 
However, KIM1 is not an independent predictor for progression of diabetic nephropathy in patients 
with type 1 diabetes when adjusted for albumin excretion rate (16). Given the available data, NGAL 
and KIM1 might provide better prediction of kidney outcome in the setting of acute kidney injury 
compared to the more chronic setting of diabetic nephropathy. Although the results from the present 
study tend to imply increased NGAL and KIM1 in diabetic rats chronically treated with TEMPOL, 
it is unclear how this translates to long-term outcome given the lack of solid literature support for a 
relationship between these biomarkers and progression of diabetic nephropathy. Indeed, previous 
reports have demonstrated a time-dependent regulation of these genes (9, 18). The efficiency of the 
antioxidant treatment is most likely time-dependent, i.e. earlier treatment initiation after the onset of 
diabetes leads to more potent effects. This may further explain why clinical trials investigating the 
use of antioxidants as a strategy to treat ongoing diabetic nephropathy have failed (20). It should 
also be noted that clinically available substances are relatively weak antioxidants compared with 
TEMPOL, which may contribute to the ineffective outcomes of these trails (10). 
The ability to assess lactate-to-pyruvate conversion non-invasively within seconds, in combination 
with standard anatomical and functional MR measurements, and the recent introduction of 
hyperpolarized MR in human subjects (11) argue in favor of the introduction of this modality for 
the assessment and therapeutic monitoring of diabetic nephropathy, facilitating the introduction of 
valuable novel metabolic information for clinicians. 
 
Summary and Significance 
Pseudohypoxia has classically been considered resultant of an altered NADH/NAD+ ratio secondary 
to increased metabolic flux via the polyol pathway. However, the present study demonstrated that 
antioxidant treatment of insulinopenic rats with TEMPOL significantly reduced the lactate-to-
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pyruvate ratio, which is an indication of reduced pseudohypoxia. A link between increased 
diabetes-induced oxidative stress and pseudohypoxia in the kidney has so far not been established. 
These results provide an additional mechanistic explanation for the beneficial effects of reduced 
oxidative stress for diabetic kidney function. However, the finding of greater metabolic 
abnormalities with disease progression indicates that interventions are likely to be more effective if 
initiated early on after the onset of diabetes. Furthermore, the results demonstrate that the use of the 
lactate-to-pyruvate ratio as a biomarker of disease development is far more sensitive compared to 
classical markers such as NGAL and KIM-1. An early and sensitive biomarker for diabetic 
nephropathy would allow for early interventional studies, which are urgently needed since no 
effective treatment strategy to fight disease progression, outside minimizing known risk factors, is 
currently available. 
 
GRANTS 
Jakob Appel Østergaard received a fellowship from the Danish Diabetes Academy supported by the 
Novo Nordisk Foundation. The study was supported by the Danish Research Council, The Danish 
Kidney Foundation, and the Helen and Ejnar Bjørnows Foundation.  
 
DISCLOSURES 
No conflicts of interest, financial or otherwise, are declared by the author(s). 
 
AUTHOR CONTRIBUTIONS 
All authors participated in the design and interpretation of the study. C.L. researched data and wrote 
the manuscript draft. P.M.N., H.Q., T.S.N., U.K, and L.B.B. researched data. H.S.J., J.A.Ø., A.F., 
and J.H.A. reviewed/edited the manuscript. F.P. contributed to discussion and wrote/edited the 
15  
manuscript. C.L. is the guarantor of this work and, as such had full access to all the data of the 
study and takes responsibility for the integrity and the accuracy of the data analysis. 
 
 
ACKNOWLEDGEMENTS 
Henrik Vestergaard Nielsen is gratefully acknowledged for technical assistance. The fellowship to 
JAØ from the Danish Diabetes Academy supported by the Novo Nordisk Foundation is much 
appreciated. 
  
16  
REFERENCES  1. Alter ML, Kretschmer A, Von Websky K, Tsuprykov O, Reichetzeder C, 
Simon A, Stasch JP, and Hocher B. Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab 58: 659-671, 2012. 2. Banday AA, Marwaha A, Tallam LS, and Lokhandwala MF. Tempol reduces oxidative stress, improves insulin sensitivity, decreases renal dopamine D1 receptor hyperphosphorylation, and restores D1 receptor-G-protein coupling and function in obese Zucker rats. Diabetes 54: 2219-2226, 2005. 3. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. 
Nature 414: 813-820, 2001. 4. Hansell P, Welch WJ, Blantz RC, and Palm F. Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension. 
Clinical and Experimental Pharmacology and Physiology 40: 123-137, 2013. 5. Laustsen C, Lipso K, Ostergaard JA, Norregaard R, Flyvbjerg A, Pedersen M, 
Palm F, and Ardenkjaer-Larsen JH. Insufficient insulin administration to diabetic rats increases substrate utilization and maintains lactate production in the kidney. Physiol Rep 2: 2014. 6. Laustsen C, Lycke S, Palm F, Ostergaard JA, Bibby BM, Norregaard R, 
Flyvbjerg A, Pedersen M, and Ardenkjaer-Larsen JH. High altitude may alter oxygen availability and renal metabolism in diabetics as measured by hyperpolarized [1-13C]pyruvate magnetic resonance imaging. Kidney Int 2013. 7. Laustsen C, Østergaard JA, Lauritzen MH, Nørregaard R, Bowen S, Søgaard 
LV, Flyvbjerg A, Pedersen M, and Ardenkjær-Larsen JH. Assessment of early diabetic renal changes with hyperpolarized [1-13C]pyruvate. Diabetes/Metabolism Research and Reviews 29: 125-129, 2013. 8. Lin MH, Chen HY, Liao TH, Huang TC, Chen CM, and Lee JA. Determination of time-dependent accumulation of D-lactate in the streptozotocin-induced diabetic rat kidney by column-switching HPLC with fluorescence detection. J Chromatogr B Analyt Technol 
Biomed Life Sci 879: 3214-3219, 2011. 9. Liu F, Yang H, Chen H, Zhang M, and Ma Q. High expression of neutrophil gelatinase-associated lipocalin (NGAL) in the kidney proximal tubules of diabetic rats. Adv 
Med Sci 60: 133-138, 2015. 10. Luo Z, Chen Y, Chen S, Welch WJ, Andresen BT, Jose PA, and Wilcox CS. Comparison of inhibitors of superoxide generation in vascular smooth muscle cells. Br J 
Pharmacol 157: 935-943, 2009. 11. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PEZ, Harzstark AL, Ferrone 
M, van Criekinge M, Chang JW, Bok R, Park I, Reed G, Carvajal L, Small EJ, Munster P, 
Weinberg VK, Ardenkjaer-Larsen JH, Chen AP, Hurd RE, Odegardstuen L-I, Robb FJ, 
Tropp J, and Murray JA. Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate. Science Translational Medicine 5: 198ra108, 2013. 12. Nielsen SE, Reinhard H, Zdunek D, Hess G, Gutierrez OM, Wolf M, Parving 
HH, Jacobsen PK, and Rossing P. Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. Diabetes Res Clin Pract 97: 71-76, 2012. 13. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, 
Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, and Brownlee M. Normalizing 
17  
mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. 
Nature 404: 787-790, 2000. 14. Palm F, Cederberg J, Hansell P, Liss P, and Carlsson PO. Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia 46: 1153-1160, 2003. 15. Palm F, Hansell P, Ronquist G, Waldenstr m A, Liss P, and Carlsson PO. Polyol-pathway-dependent disturbances in renal medullary metabolism in experimental insulin-deficient diabetes mellitus in rats. Diabetologia 47: 2004. 16. Panduru NM, Sandholm N, Forsblom C, Saraheimo M, Dahlstrom EH, Thorn 
LM, Gordin D, Tolonen N, Waden J, Harjutsalo V, Bierhaus A, Humpert PM, Groop PH, 
and FinnDiane Study G. Kidney injury molecule-1 and the loss of kidney function in diabetic nephropathy: a likely causal link in patients with type 1 diabetes. Diabetes Care 38: 1130-1137, 2015. 17. Persson MF, Franzen S, Catrina SB, Dallner G, Hansell P, Brismar K, and 
Palm F. Coenzyme Q10 prevents GDP-sensitive mitochondrial uncoupling, glomerular hyperfiltration and proteinuria in kidneys from db/db mice as a model of type 2 diabetes. 
Diabetologia 55: 1535-1543, 2012. 18. Rosenberger C, Khamaisi M, Abassi Z, Shilo V, Weksler-Zangen S, Goldfarb 
M, Shina A, Zibertrest F, Eckardt KU, Rosen S, and Heyman SN. Adaptation to hypoxia in the diabetic rat kidney. Kidney Int 73: 34-42, 2008. 19. Schrijvers BF, De Vriese AS, and Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25: 971-1010, 2004. 20. Tavafi M. Diabetic nephropathy and antioxidants. J Nephropathol 2: 20-27, 2013. 21. Toma I, Kang JJ, Sipos A, Vargas S, Bansal E, Hanner F, Meer E, and Peti-
Peterdi J. Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney. J Clin Invest 118: 2526-2534, 2008. 22. Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, Cunard R, 
Sharma K, Thomson SC, and Rieg T. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 304: F156-167, 2013. 23. Vandekerckhove L, Vermeulen Z, Liu ZZ, Boimvaser S, Patzak A, Segers VF, 
and De Keulenaer GW. Neuregulin-1 attenuates development of nephropathy in a type 1 diabetes mouse model with high cardiovascular risk. Am J Physiol Endocrinol Metab 310: E495-504, 2016. 24. Wilcox CS. Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol Ther 126: 119-145, 2010. 25. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, 
Nyengaard JR, Den Enden Mv, Kilo C, and Tilton RG. Hyperglycemic Pseudohypoxia and Diabetic Complications. Diabetes 42: 801-813, 1993. 26. You YH, Quach T, Saito R, Pham J, and Sharma K. Metabolomics Reveals a Key Role for Fumarate in Mediating the Effects of NADPH Oxidase 4 in Diabetic Kidney Disease. J 
Am Soc Nephrol 27: 466-481, 2016. 
  
 
18  
Figure legends 
 
Figure 1. Study design, consisting of up to three consecutive hyperpolarized MRI examinations in a 
healthy and untreated diabetic group, and the inclusion of untreated diabetic animals and a third 
group treated for three weeks with TEMPOL examined at the 4-week endpoint.  
 
Figure 2. End-point blood glucose levels, kidney weights, and body weights at the end of study in 
control (N=6) and diabetic animals with and without chronic TEMPOL treatment (N=10). *denotes 
p<0.05 between controls versus untreated and treated diabetes, respectively. The data are shown as 
mean±SEM. 
 
Figure 3. Lactate-to-pyruvate, alanine-to-pyruvate, and bicarbonate-to-pyruvate levels in healthy 
controls (N=5) and untreated diabetic rats (N=10) during the first week after the onset of 
insulinopenic diabetes. *denotes p<0.05 in subject as a function of time and between controls and 
diabetic animals. The data are shown as mean±SEM. (Lactate) p=0.03* for group (between 
subjects factor), p=0.02 for time (within-subjects factor) and p=0.01 for interaction; (Alanine) 
p=0.66 for group, p=0.46 for time and p=0.81 for interaction; (Bicarbonate) p=0.98 for group, 
p=0.02 for time and p=0.50 for interaction. 
 
Figure 4. Endpoint lactate-to-pyruvate, alanine-to-pyruvate, and bicarbonate-to-pyruvate ratios in 
control (N=4) and diabetic animals (N=11) with and without chronic TEMPOL treatment (N=8). 
*denotes p<0.05 between diabetics versus controls and diabetics treated with TEMPOL. **denotes 
p<0.05 between controls and diabetic treated with TEMPOL. The data are shown as mean±SEM. 
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Figure 5. mRNA expressions of lactate dehydrogenase, alanine transferase, and pyruvate 
dehydrogenase in control (N=5) and diabetic animals (N=13) with and without chronic TEMPOL 
treatment (N=8). *denotes p<0.05 between diabetics versus controls and diabetics treated with 
TEMPOL. The data are shown as mean±SEM. 
 
Figure 6. mRNA expressions of oxygen-sensitive genes ((NAD(P)H quinone acceptor 
oxidoreductase 1 (NQO1), Vascular endothelial growth factor (VEGF), heme oxygenase-1 (HO1)), 
and markers of kidney injury (KIM-1 and NGAL), and fibrosis ((α-Smooth Muscle Actin (ACTA2)) 
and inflammation (tumor necrosis factor α (TNFα)) in control (N=5) and diabetic animals (N=13) 
with and without chronic TEMPOL treatment (N=8). The data are shown as mean±SEM. 
 
Figure 7. Tissue and plasma concentrations of lactate and the TCA metabolites fumarate and 
succinate in control (N=6) and in diabetic animals (N=14) with and without chronic TEMPOL 
treatment (N=8). The data are shown as mean±SEM. 
 
Figure 8. Cortical tissue NGAL and KIM-1 protein concentration in control (N=6) and in diabetic 
animals (N=14) with and without chronic TEMPOL treatment (N=8). The data are shown as 
mean±SEM.  
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Table 1. PCR primers. 
Gene Forward primer sequence Reverse primer sequence 
ACTB 5′-AGCCATGTACGTAGCCATCC-3′ 5′-TGTGGTGGTGAAGCTGTAGC-3′ 
LDH 5′-AATATTACGTGAAATGTAAGAT-3′ 5′-TTTTCCTTGGCATGACACTTGAG-3′ 
PDH 5′-TCCACTCCTTGTAGCTGCAAC-3′ 5′-GAGAACCCACCACCCCATG-3′ 
ALT 5′-GCCATGTATTCCTTCCCTCA-3′ 5′-GCCTCATTGAAGACCTGCTC-3′ 
KIM-1 5′-CCACAAGGCCCACAACTATT-3′ 5′-TGTCACAGTGCCATTCCAGT-3′ 
NGAL 5′-GATCAGAACATTCGTTCCAA-3′ 5′-TTGCACATCGTAGCTCTGTA-3′ 
HO1 5′-TCTATCGTGCTCGCATGAAC-3′ 5′-AAGGCGGTCTTAGCCTCTTC-3′ 
VEGF 5′-GCCCATGAAGTGGTGAAGTT-3′ 5′-ACTCCAGGGCTTCATCATTG-3′ 
ACTA2 5′-CATCATGCGTCTGGACTTGG-3′ 5′-CCAGGGAAGAAGAGGAAGCA-3′ 
TNFα 5′-GCCCTAAGGACACCCCTGAGGGAGC-3′ 5′-TCCAAAGTAGACCTGCCCGCACTCC-3′ 
NQO1 5′-GTGGTGATGGAAAGCAAGGT-3′ 5′-GCCCGGATATTGTAGCTGAA-3′ 
 
